Want to see KRRO full AI Analyst Report?
Top Page
Korro Bio
(NASDAQ:KRRO)
Select Model
Select Model
Rating:47Neutral
Price Target:
$9.50
▼(-28.36% Downside)
Action:Reiterated
Date:10/05/26
KRRO scores low-to-mid primarily due to weak financial performance (large losses and heavy cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive clinical progress for KRRO-121 provides an offsetting catalyst, but it is not enough to outweigh the current loss-making, cash-consuming profile and weak price trend.
Positive Factors
Clinical pipeline advancement
First-in-human dosing moves KRRO-121 from preclinical development into clinical testing, creating a meaningful validation point for Korro’s RNA-editing approach. The program’s progression can generate safety, pharmacokinetic, and proof-of-concept data that support future pipeline development.
Negative Factors
Persistent unprofitability
Korro remains firmly loss-making, with operating expenses far exceeding its modest revenue base. Deep negative operating and net margins show that the current business model is not yet self-funding, leaving future value dependent on successful development and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline advancement
First-in-human dosing moves KRRO-121 from preclinical development into clinical testing, creating a meaningful validation point for Korro’s RNA-editing approach. The program’s progression can generate safety, pharmacokinetic, and proof-of-concept data that support future pipeline development.
Read all positive factors
Korro Bio (KRRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$137.98M
Dividend YieldN/A
Average Volume (3M)173.58K
Price to Earnings (P/E)―
Beta (1Y)2.89
Revenue Growth-62.08%
EPS Growth-2.62%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.01
Shares Outstanding14,725,646
10 Day Avg. Volume128,798
30 Day Avg. Volume173,576
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue66.91
Enterprise Value/Gross Profit91.97
Enterprise Value/Ebitda-2.22
Forecast
1Y Price Target
$19.33Price Target Upside45.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$333.33K
Korro Bio Business Overview & Revenue Model
Company Description
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wid...
How the Company Makes Money
Korro Bio’s revenue model is typical of a clinical-stage biotech company: it does not primarily generate revenue from commercial product sales because its therapeutic candidates are in development rather than broadly marketed. Instead, the company...
Korro Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.38M | 6.39M | 2.27M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.73M | 2.11M | 2.27M | 0.00 | 0.00 | 0.00 |
| EBITDA | -71.92M | -83.06M | -88.34M | -80.90M | -56.49M | -33.90M |
| Net Income | -106.64M | -117.26M | -83.58M | -81.17M | -58.03M | -21.96M |
Balance Sheet | ||||||
| Total Assets | 163.45M | 113.51M | 226.24M | 221.66M | 73.74M | 185.36M |
| Cash, Cash Equivalents and Short-Term Investments | 115.04M | 75.16M | 126.09M | 166.15M | 55.85M | 130.71M |
| Total Debt | 42.21M | 43.49M | 44.77M | 33.21M | 166.99M | 45.60M |
| Total Liabilities | 60.22M | 62.07M | 65.83M | 51.75M | 172.77M | 54.53M |
| Stockholders Equity | 103.23M | 51.44M | 160.41M | 169.91M | -99.03M | 130.82M |
Cash Flow | ||||||
| Free Cash Flow | -68.27M | -79.08M | -77.98M | -75.12M | -58.86M | -36.54M |
| Operating Cash Flow | -67.95M | -78.56M | -60.07M | -67.28M | -53.65M | -32.09M |
| Investing Cash Flow | -27.63M | 43.99M | -123.35M | 11.16M | 11.06M | -39.50M |
| Financing Cash Flow | 85.80M | 685.00K | 69.36M | 187.76M | 18.00K | 115.94M |
Korro Bio Technical Analysis
Negative
13.26
Price Trends
11.88
Negative
12.04
Negative
11.75
Negative
Market Momentum
-0.61
Negative
36.74
Neutral
52.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Negative. The current price of 13.26 is above the 20-day moving average (MA) of 10.38, above the 50-day MA of 11.88, and above the 200-day MA of 11.75, indicating a bearish trend. The MACD of -0.61 indicates Negative momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 52.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRRO.
Korro Bio Risk Analysis
Korro Bio disclosed 85 risk factors in its most recent earnings report. Korro Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Korro Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $718.17M | -4.78 | -41.33% | ― | 278712.12% | 26.59% | |
54 Neutral | $750.73M | -3.41 | -106.15% | ― | ― | 10.96% | |
54 Neutral | $678.23M | -3.67 | -73.18% | ― | ― | 9.05% | |
52 Neutral | $682.77M | -9.25 | -34.03% | ― | ― | -5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $463.61M | 41.40 | -0.02% | ― | 125.12% | 98.69% | |
47 Neutral | $137.98M | -0.94 | -114.26% | ― | -62.08% | -2.62% |
* Healthcare Sector Average
KRRO
Korro Bio
9.37
-36.41
-79.53%
ASMB
Assembly Biosciences
22.77
-5.62
-19.80%
ANNX
Annexon Biosciences
3.96
0.96
32.00%
FDMT
4D Molecular Therapeutics
13.00
3.03
30.39%
DSGN
Design Therapeutics
10.91
4.29
64.80%
AURA
Aura Biosciences Inc
6.54
0.38
6.17%
Korro Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Korro Bio Begins First Human Trial of KRRO-121 Therapy
Positive
Oct 5, 2026
On October 5, 2026, Korro Bio announced it has dosed the first cohort of healthy volunteers in ANCHOR, its global Phase 1/2 clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia in urea cycle disorders and ...
Business Operations and StrategyProduct-Related Announcements
Korro Bio Advances KRRO-121 Into First Human Trial
Positive
Aug 19, 2026
On August 19, 2026, Korro Bio, Inc. reported it had submitted an application to the Australian Alfred Health Human Ethics Committee to begin a first-in-human Phase 1/2 clinical trial of KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide for...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Korro Bio Refines Capital Structure with Exchange Agreement
Positive
Aug 6, 2026
On August 5, 2026, Korro Bio entered into an exchange agreement with Venrock Healthcare Capital Partners in which Venrock surrendered 1,000,000 Korro common shares for no consideration in exchange for pre-funded warrants to purchase the same numbe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.